Given that current treatments for viral infections are based on preventive measures such as yearly vaccination, targeting IL-33 might represent a novel strategy to halt or reduce the dramatic effects of COPD exacerbations due to these pathogens. Here, IL33 is linked to chronic obstructive pulmonary disease.